Cutting Balloon Combined with Drug-Coated Balloon Angioplasty for the Treatment of In-Stent Restenosis

被引:10
作者
Zheng, You-Cheng [1 ]
Lee, Wei-Chieh [1 ,2 ]
Fang, Hsiu-Yu [1 ]
Chen, Chien-Jen [1 ]
Yang, Cheng-Hsu [1 ]
Wu, Chiung-Jen [1 ]
Fang, Chih-Yuan [1 ]
机构
[1] Chang Gung Univ, Coll Med, Kaohsiung Chang Gung Mem Hosp, Div Cardiol,Dept Internal Med, 123 Ta Pei Rd, Kaohsiung 83301, Taiwan
[2] Natl Cheng Kung Univ, Coll Med, Inst Clin Med, Tainan, Taiwan
关键词
Cutting balloon angioplasty; Restenosis lesion; Percutaneous coronary intervention; Clinical outcome; BARE-METAL STENT; ROTATIONAL ATHERECTOMY; ELUTING BALLOONS; ISAR-DESIRE; IMPLANTATION; MANAGEMENT; CATHETER;
D O I
10.1536/ihj.21-207
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Drug-coated balloon (DCB) has emerged as an alternative therapeutic choice for in-stent restenosis (ISR) lesions. Cutting balloon angioplasty (CBA) is also a strategy utilized to treat tight stenotic lesions or ISR lesions. Few studies have focused on whether CBA plus DCB could achieve a better result in lowering the incidence of recurrent ISR. This study aimed to evaluate the efficacy of CBA plus DCB for ISR lesions. Between August 2011 and December 2017, 681 patients (937 lesions) were diagnosed with ISR and treated with DCBs in our hospital. The CBA plus DCB group comprised 90 patients who underwent PCI with further CBA plus DCB, and the DCB alone group comprised 591 patients who underwent percutaneous coronary intervention (PCI) with DCB alone. Baseline characteristics, the types of previous stents, lesion type, prevalence of ostial lesion and left main lesion, and pre-PCI and post-PCI stenotic percentage showed no significant difference between the two groups. Only post-PCI reference luminal diameter and size of DCB were larger in the CBA plus DCB group. During the one-year follow-up period, late loss and clinical outcomes did not differ between the two groups before and after propensity score matching. The incidence of subtotal/total occlusion with delay flow was lower in the CBA plus DCB group after propensity score matching (4.1% versus 10.9%; P = 0.030). In these patients with ISR lesions, the clinical outcomes and the incidence of repeat target lesion revascularization were similar after treatment with CBA plus DCB versus DCB alone. Further study is warranted, including prospective, randomized comparisons.
引用
收藏
页码:1213 / 1220
页数:8
相关论文
共 25 条
[1]   Cutting balloon angioplasty for the treatment of in-stent restenosis: A matched comparison with rotational atherectomy, additional stent implantation and balloon angioplasty [J].
Adamian, M ;
Colombo, A ;
Briguori, C ;
Nishida, T ;
Marsico, F ;
Di Mario, C ;
Albiero, R ;
Moussa, I ;
Moses, JW .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 38 (03) :672-679
[2]   Comparison of clinical and angiographic outcome of sirolimus-eluting stent implantation versus cutting balloon angioplasty for coronary in-stent restenosis [J].
Airoldi, F ;
Rogacka, R ;
Briguori, C ;
Chieffo, A ;
Carlino, M ;
Montorfano, M ;
Mikhail, G ;
Iakovou, I ;
Michev, I ;
Vitrella, G ;
Albiero, R ;
Colombo, A .
AMERICAN JOURNAL OF CARDIOLOGY, 2004, 94 (10) :1297-1300
[3]   Cardiovascular disease: A global problem extending into the developing world [J].
Aje, Temilolu Olayinka ;
Miller, Michael .
WORLD JOURNAL OF CARDIOLOGY, 2009, 1 (01) :3-10
[4]   Current Treatment of In-Stent Restenosis [J].
Alfonso, Fernando ;
Byrne, Robert A. ;
Rivero, Fernando ;
Kastrati, Adnan .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (24) :2659-2673
[5]  
Alraies MC, 2017, WORLD J CARDIOL, V9, P640, DOI 10.4330/wjc.v9.i8.640
[6]   Differential relative efficacy between drug-eluting stents in patients with bare metal and drug-eluting stent restenosis; evidence in support of drug resistance: insights from the ISAR-DESIRE and ISAR-DESIRE 2 trials [J].
Byrne, Robert A. ;
Cassese, Salvatore ;
Windisch, Thomas ;
King, Larain A. ;
Joner, Michael ;
Tada, Tomohisa ;
Mehilli, Julinda ;
Pache, Juergen ;
Kastrati, Adnan .
EUROINTERVENTION, 2013, 9 (07) :797-802
[7]   Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial [J].
Byrne, Robert A. ;
Neumann, Franz-Josef ;
Mehilli, Julinda ;
Pinieck, Susanne ;
Wolff, Britta ;
Tiroch, Klaus ;
Schulz, Stefanie ;
Fusaro, Massimiliano ;
Ott, Ilka ;
Ibrahim, Tareq ;
Hausleiter, Joerg ;
Valina, Christian ;
Pache, Juergen ;
Laugwitz, Karl-Ludwig ;
Massberg, Steffen ;
Kastrati, Adnan .
LANCET, 2013, 381 (9865) :461-467
[8]   Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography [J].
Cassese, Salvatore ;
Byrne, Robert A. ;
Tada, Tomohisa ;
Pinieck, Susanne ;
Joner, Michael ;
Ibrahim, Tareq ;
King, Lamin A. ;
Fusaro, Massimiliano ;
Laugwitz, Karl-Ludwig ;
Kastrati, Adnan .
HEART, 2014, 100 (02) :153-159
[9]   Angiographic analysis of the angioplasty versus rotational atherectomy for the treatment of diffuse in-stent restenosis trial (ARTIST) [J].
Dietz, U ;
Rupprecht, HJ ;
de Belder, MA ;
Wijns, W ;
van Ufford, MAQ ;
Klues, HG ;
vom Dahl, J .
AMERICAN JOURNAL OF CARDIOLOGY, 2002, 90 (08) :843-847
[10]   Drug-eluting balloons versus new generation drug-eluting stents for the management of in-stent restenosis: an updated meta-analysis of randomized studies [J].
Gao, Lei ;
Wang, Ya-Bin ;
Jing, Jing ;
Zhang, Ming ;
Chen, Yun-Dai .
JOURNAL OF GERIATRIC CARDIOLOGY, 2019, 16 (06) :448-457